


PIPELINE

Candidate: Lasofoxifene – Oral SERM



In Planning
Enrollment Complete

▶ Treatment Resistant Tumors (non-ESR1^{mut}) and ESR1^{mut}

•

Laso vs. Fulv

••

Laso + Palbo
vs. Fulv + Palbo

▶ Gynecological Cancer

•/••

Lasofloxifene –
Endometrial
Cancer

▶ ESR1 Assay

Research Assay

Clinical Trial
Assay (CTA)

CTA/CDx

THE UNIVERSITY OF
CHICAGO

UNIVERSITY OF UTAH
HUNTSMAN
CANCER INSTITUTE